Lista de obras - Maria Carmela Piccirillo

A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial

artículo científico publicado en 2017

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives

artículo científico

Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors

artículo científico

Angiogenesis Inhibitors in NSCLC.

artículo científico publicado en 2017

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

artículo científico publicado en 2014

Cetuximab in non-small-cell lung cancer

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials

artículo científico publicado en 2010

Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….

artículo científico

EGFR mutations in lung cancer: from tissue testing to liquid biopsy

artículo científico

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

artículo científico publicado en 2011

Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer

artículo científico publicado en 2007

Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial

artículo científico publicado en 2009

First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment

artículo científico publicado en 2007

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

artículo científico publicado en 2012

Gefitinib in non small cell lung cancer

artículo científico publicado en 2011

Integrated therapeutic approaches in the treatment of locally advanced non-small cell lung cancer

artículo científico publicado en 2013

Methodological aspects of lung cancer clinical trials in the era of targeted agents

artículo científico publicado en 2009

New biological treatments for gynecological tumors: focus on angiogenesis

artículo científico

New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development

artículo científico publicado en 2010

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

artículo científico publicado en 2015

Pharmacokinetic evaluation of capecitabine in breast cancer

artículo científico

Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial ⬇️

artículo científico publicado el 1 de enero de 2012

Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials

artículo científico publicado en 2012

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study

artículo científico

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study

artículo científico publicado en 2013

Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy

artículo científico publicado en 2016

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

artículo científico publicado en 2015

Time spent for activation of non-profit studies in oncology in Italy

artículo científico publicado en 2010

Treatment of small cell lung cancer

scholarly article by Alessandro Morabito et al published September 2014 in Critical Reviews in Oncology Hematology

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial

artículo científico publicado en 2007

Lista de obras de Maria Carmela Piccirillo

A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives

Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors

Angiogenesis Inhibitors in NSCLC.

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Cetuximab in non-small-cell lung cancer

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials

Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….

EGFR mutations in lung cancer: from tissue testing to liquid biopsy

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer

Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial

First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

Gefitinib in non small cell lung cancer

Integrated therapeutic approaches in the treatment of locally advanced non-small cell lung cancer

Methodological aspects of lung cancer clinical trials in the era of targeted agents

New biological treatments for gynecological tumors: focus on angiogenesis

New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

Pharmacokinetic evaluation of capecitabine in breast cancer

Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial ⬇️

Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study

Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

Time spent for activation of non-profit studies in oncology in Italy

Treatment of small cell lung cancer

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial